Blueprint Genetics
Uses Next Generation Sequencing (NGS) to perform diagnostics on genetic diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
$62—92m (Dealroom.co estimates Jul 2017.)
Company register number 2230790-0
Espoo Uusimaa (HQ)
Financials
Estimates*
EUR | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|
Revenues | 8.1m | 10.3m | 15.4m | 16.1m | 22.9m | 22.8m | 22.8m |
% growth | 248 % | 27 % | 50 % | 5 % | 42 % | (1 %) | - |
EBITDA | (3.0m) | (6.5m) | (4.0m) | (5.5m) | 3.3m | (4.5m) | - |
% EBITDA margin | (37 %) | (64 %) | (26 %) | (34 %) | 15 % | (20 %) | - |
Profit | (4.7m) | (9.2m) | (7.0m) | (8.3m) | 1.5m | (6.0m) | - |
% profit margin | (59 %) | (90 %) | (45 %) | (51 %) | 6 % | (26 %) | - |
R&D budget | 8.0m | 10.0m | 20.0m | 20.0m | - | - | - |
R&D % of revenue | 99 % | 98 % | 130 % | 124 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
€2.4m | Early VC | ||
$3.9m | Seed | ||
€3.5m | Early VC | ||
€6.0m | Early VC | ||
€3.5m Valuation: €30.0m 12.9x EV/LTM Revenues -12.6x EV/LTM EBITDA | Early VC | ||
* | €14.0m | Series A | |
N/A | N/A | Series B | |
* | N/A | N/A | Debt |
Total Funding | $36.2m |
Recent News about Blueprint Genetics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.